FDA approval outcome
קריטי GRAL GRAIL Inc.
CMS coverage criteria and timing
קריטי Commercial payer adoption
קריטי Peer-reviewed PATHFINDER 2 and NHS-Galleri publications
גבוה Mortality benefit or strong health-economic evidence
גבוה Payer mix and reimbursed share of volume
גבוה Repeat-testing behavior
גבוה Channel-level ASP and gross margin
גבוה Long-term dilution risk
בינוני NTRA Natera Inc.
Signatera-specific revenue, ASP and oncology gross margin
קריטי Growth and margin assumptions embedded in the premium valuation
קריטי Medicare / commercial / self-pay payer mix and denial rates
גבוה Repeat testing and tests per oncology patient
גבוה Signatera MRD market share by indication
גבוה Guardant Reveal and Exact/Abbott Oncodetect adoption
גבוה Tumor-informed vs tissue-free performance and workflow by indication
גבוה Operating leverage, normalized free cash flow, SBC and dilution
גבוה Japan pricing, launch pace and uptake
בינוני AXTI AXT Inc.
Official Q2/Q3 total and InP revenue, gross margin and profitability vs guidance
קריטי Backlog terms, concentration, permit status and conversion
קריטי Permit cadence by product, customer, geography, volume and duration
קריטי Revenue and margin assumptions embedded in current valuation
קריטי Capacity, utilization, yield, capex and 6-inch InP qualification
גבוה Product-level gross margin and normalized operating leverage
גבוה Post-offering cash, fully diluted shares and Tongmei/common-shareholder economics
גבוה Coherent sourcing after internal ramp; Sumitomo and Chinese external supply
גבוה Structural demand vs shortage, double ordering and pricing normalization
גבוה Casela prepayments, delivery, margin and capacity-allocation effects
בינוני PKE Park Aerospace Corp.
Do FY2027 Q1/Q2 confirm FY2026 and Q4 durability?
קריטי How much of the ~$51.4M backlog converts, when, and at what margin?
קריטי Are FY2027 GE/MRAS sales tracking toward the $34M-$38M estimate?
קריטי How much revenue is Aerojet/L3Harris/PAC-3, and how much is Park-manufactured?
קריטי Final plant budget, timeline, funding, utilization threshold and ROIC?
קריטי Does normalized FCF cover the dividend after plant capex?
קריטי Will ATM issuance continue, and what is fully diluted share count?
קריטי Gross margin by product family, especially C2(R)B fabric vs Park ablatives
גבוה C2(R)B U.S. manufacturing agreement, ArianeGroup capacity and supply timing
גבוה Current valuation expectations versus FY2027 evidence
גבוה שאלות פתוחות נגזרות מ-working-notes ומ-IC memo של כל חברה. רמת העדיפות מסומנת כקריטי / גבוה / בינוני.